Literature DB >> 29525644

Biophysical Derangements in Genetic Cardiomyopathies.

Melissa L Lynn1, Sarah J Lehman2, Jil C Tardiff3.   

Abstract

This article focuses on three "bins" that comprise sets of biophysical derangements elicited by cardiomyopathy-associated mutations in the myofilament. Current therapies focus on symptom palliation and do not address the disease at its core. We and others have proposed that a more nuanced classification could lead to direct interventions based on early dysregulation changing the trajectory of disease progression in the preclinical cohort. Continued research is necessary to address the complexity of cardiomyopathic progression and develop efficacious therapeutics. Published by Elsevier Inc.

Entities:  

Keywords:  Calcium signaling; Cardiomyopathies; Phosphorylation potential; Primary; Protein stability; Therapeutics

Mesh:

Year:  2018        PMID: 29525644      PMCID: PMC6204208          DOI: 10.1016/j.hfc.2017.12.002

Source DB:  PubMed          Journal:  Heart Fail Clin        ISSN: 1551-7136            Impact factor:   3.179


  109 in total

Review 1.  The Rapidly Evolving Role of Titin in Cardiac Physiology and Cardiomyopathy.

Authors:  Brenda Gerull
Journal:  Can J Cardiol       Date:  2015-08-28       Impact factor: 5.223

2.  Increase in tension-dependent ATP consumption induced by cardiac troponin T mutation.

Authors:  Murali Chandra; Matthew L Tschirgi; Jil C Tardiff
Journal:  Am J Physiol Heart Circ Physiol       Date:  2005-07-01       Impact factor: 4.733

3.  The relationship between curvature, flexibility and persistence length in the tropomyosin coiled-coil.

Authors:  Xiaochuan Edward Li; William Lehman; Stefan Fischer
Journal:  J Struct Biol       Date:  2010-02-01       Impact factor: 2.867

4.  Familial hypertrophic cardiomyopathy-linked mutant troponin T causes stress-induced ventricular tachycardia and Ca2+-dependent action potential remodeling.

Authors:  Björn C Knollmann; Paulus Kirchhof; Syevda G Sirenko; Hubertus Degen; Anne E Greene; Tilmann Schober; Jessica C Mackow; Larissa Fabritz; James D Potter; Martin Morad
Journal:  Circ Res       Date:  2003-02-06       Impact factor: 17.367

Review 5.  Ca(2+) exchange with troponin C and cardiac muscle dynamics.

Authors:  Jonathan P Davis; Svetlana B Tikunova
Journal:  Cardiovasc Res       Date:  2007-12-12       Impact factor: 10.787

6.  Troponin I Mutations R146G and R21C Alter Cardiac Troponin Function, Contractile Properties, and Modulation by Protein Kinase A (PKA)-mediated Phosphorylation.

Authors:  Yuanhua Cheng; Vijay Rao; An-Yue Tu; Steffen Lindert; Dan Wang; Lucas Oxenford; Andrew D McCulloch; J Andrew McCammon; Michael Regnier
Journal:  J Biol Chem       Date:  2015-09-21       Impact factor: 5.157

Review 7.  A review of levosimendan in the treatment of heart failure.

Authors:  Hulya Akhan Kasikcioglu; Nese Cam
Journal:  Vasc Health Risk Manag       Date:  2006

Review 8.  To understand muscle you must take it apart.

Authors:  Christopher Batters; Claudia Veigel; Earl Homsher; James R Sellers
Journal:  Front Physiol       Date:  2014-03-11       Impact factor: 4.566

9.  Structural and protein interaction effects of hypertrophic and dilated cardiomyopathic mutations in alpha-tropomyosin.

Authors:  Audrey N Chang; Norma J Greenfield; Abhishek Singh; James D Potter; Jose R Pinto
Journal:  Front Physiol       Date:  2014-12-02       Impact factor: 4.566

Review 10.  The Importance of Intrinsically Disordered Segments of Cardiac Troponin in Modulating Function by Phosphorylation and Disease-Causing Mutations.

Authors:  Maria Papadaki; Steven B Marston
Journal:  Front Physiol       Date:  2016-11-02       Impact factor: 4.566

View more
  6 in total

1.  Disrupted mechanobiology links the molecular and cellular phenotypes in familial dilated cardiomyopathy.

Authors:  Sarah R Clippinger; Paige E Cloonan; Lina Greenberg; Melanie Ernst; W Tom Stump; Michael J Greenberg
Journal:  Proc Natl Acad Sci U S A       Date:  2019-08-19       Impact factor: 11.205

2.  Functional Characterization of Cardiac Actin Mutants Causing Hypertrophic (p.A295S) and Dilated Cardiomyopathy (p.R312H and p.E361G).

Authors:  Roua Hassoun; Constanze Erdmann; Sebastian Schmitt; Setsuko Fujita-Becker; Andreas Mügge; Rasmus R Schröder; Matthias Geyer; Mina Borbor; Kornelia Jaquet; Nazha Hamdani; Hans Georg Mannherz
Journal:  Int J Mol Sci       Date:  2022-04-18       Impact factor: 6.208

Review 3.  Beyond genomics-technological advances improving the molecular characterization and precision treatment of heart failure.

Authors:  Kory J Lavine; Michael J Greenberg
Journal:  Heart Fail Rev       Date:  2020-09-03       Impact factor: 4.214

Review 4.  Genetic and Tissue Engineering Approaches to Modeling the Mechanics of Human Heart Failure for Drug Discovery.

Authors:  Michael J Greenberg; Neil J Daily; Ann Wang; Michael K Conway; Tetsuro Wakatsuki
Journal:  Front Cardiovasc Med       Date:  2018-09-19

5.  Loss of crossbridge inhibition drives pathological cardiac hypertrophy in patients harboring the TPM1 E192K mutation.

Authors:  Lorenzo R Sewanan; Jinkyu Park; Michael J Rynkiewicz; Alice W Racca; Nikolaos Papoutsidakis; Jonas Schwan; Daniel L Jacoby; Jeffrey R Moore; William Lehman; Yibing Qyang; Stuart G Campbell
Journal:  J Gen Physiol       Date:  2021-07-28       Impact factor: 4.086

6.  A troponin T variant linked with pediatric dilated cardiomyopathy reduces the coupling of thin filament activation to myosin and calcium binding.

Authors:  Samantha K Barrick; Lina Greenberg; Michael J Greenberg
Journal:  Mol Biol Cell       Date:  2021-06-23       Impact factor: 4.138

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.